Free shipping on all orders over $ 500

LDN-193189

Cat. No. M1873

All AbMole products are for research use only, cannot be used for human consumption.

LDN-193189 Structure
Synonym:

DM-3189; LDN193189

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 50  USD50 In stock
5mg USD 80  USD80 In stock
10mg USD 120  USD120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. BMPs induce Smad1/5/8 plus non-Smad pathways, such as MAPK and Akt. BMP signaling pathway is the key regulators of cell fate decisions during embryogenesis and tissue homeostasis. LDN-193189 inhibits ectopic ossification and a potential agent in the treatment of NSCLC lung tumors, showing significant in vivo clinical utility. In addition, it inhibits the activation of p38, ERK1/2 and Akt in C2C12 cells. LDN-193189 only weakly inhibits ALK4, ALK5, and ALK7. LDN-193189 affects not only the Smad but also the non-Smad signalling pathways induced by either BMP2, BMP6 or GDF5.

Product Citations
Customer Product Validations & Biological Datas
Source J Biol Chem (2015). Figure 4. LDN-193189
Method immunoblotting
Cell Lines C2C12 cells
Concentrations 5 μM
Incubation Time 30 min
Results Pretreatment with dorsomorphin or LDN-193189 led to reduced levels of phosphorylated Smad2/3 following GDF8 stimulation (Fig. 4A), which were comparable with their effects on BMP2-induced phosphorylation of Smad1/5 (Fig. 4B), whereas there was no effect on TGF- induced Smad2/3 signals (Fig. 4A).
Source J Biol Chem (2015). Figure 2. LDN-193189
Method immunoblotting
Cell Lines C2C12 cells
Concentrations 0.5 μM
Incubation Time 30 min
Results A similar effect of dorsomorphin and LDN-193189 treatment was observed in undifferentiated primary human myoblasts as well as in the mouse myoblast cell line C2C12
Protocol (for reference only)
Cell Experiment
Cell lines C2C12 cells
Preparation method Alkaline phosphatase activity We seeded C2C12 cells into 96-well plates at 2,000 cells per well in DMEM supplemented with 2% FBS. We treated the wells in quadruplicate with BMP ligands and LDN-193189 or vehicle. We collected the cells after 6 d in culture in 50 μl Tris-buffered saline and 1% Triton X-100. We added the lysates to p-nitro-phenylphosphate reagent in 96-well plates for 1 h and then evaluated alkaline phosphatase activity (absorbance at 405 nm). We measured cell viability and quantity by Cell Titer Aqueous One (absorbance at 490 nm), using replicate wells treated identically to those used for alkaline phosphatase measurements.
Concentrations 0,2,8,31,125,500nM
Incubation time 6 days
Animal Experiment
Animal models C57BL/6 mouse FOP model
Formulation unknown
Dosages 3 mg /kg every 12 h
Administration intraperitoneally
Chemical Information
Molecular Weight 406.48
Formula C25H22N6
CAS Number 1062368-24-4
Solubility (25°C) DMSO 4.5 mg/mL (ultrasonic and warming and adjust pH to 2 with 1M HCl)
Water ~1 mg/mL (warming and adjust pH to 2 with HCl)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Julien Vollaire, et al. The Bone Morphogenetic Protein Signaling Inhibitor LDN-193189 Enhances Metastasis Development in Mice

[2] Eleanor Williams, et al. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2

[3] Daniel Horbelt, et al. Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation

[4] Jennifer L Ali, et al. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells

[5] J H Boergermann, et al. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells

Related ALK Products
F-1

F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50 values of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively.

TL13-22 

TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM.

TL13-110 

TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM.

ALK inhibitor 2 

ALK inhibitor 2 is a potent pyrimidin ALK inhibitor.

NVL-655 TFA

NVL-655 (ALK-IN-27) TFA is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 (ALK-IN-27) TFA has an IC50 of 2.7 nM. It can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC).

  Catalog
Abmole Inhibitor Catalog




Keywords: LDN-193189, DM-3189; LDN193189 supplier, ALK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.